CLADRIBINE
| Brand name | MAVENCLAD |
|---|---|
| Active ingredient | CLADRIBINE |
| Strength | 10MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | March 2019 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12533408 | September 2041 | use U-4395 |
| 12539329 | September 2041 | use U-4399 |
| 10849919 | November 2038 | use U-3411 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.